Telormedix SA
This article was originally published in Start Up
Executive Summary
Swiss-based Telormedix is developing small-molecule drugs for cancer and auto-immune disease, harnessing the innate immune system--and toll-like receptor 7 (TLR-7) in particular.
You may also be interested in...
Start-Up Previews (01/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Biotechs Target the GI Tract," features profiles of Alvine Pharmaceuticals, Genetic Analysis, Meritage Pharma and Ventrus Biosciences. Plus these Start-Ups Across Health Care: Advanced Cardiac Therapeutics, Concert Pharmaceuticals, ImThera Medical, On-Q-ity and Telormedix.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”